CareDx Inc (CDNA)vsDanaher Corporation (DHR)
CDNA
CareDx Inc
$28.82
-3.76%
HEALTHCARE · Cap: $1.20B
DHR
Danaher Corporation
$196.19
+1.75%
HEALTHCARE · Cap: $138.86B
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 5902% more annual revenue ($24.78B vs $412.82M). DHR leads profitability with a 14.9% profit margin vs -2.0%. DHR earns a higher WallStSmart Score of 58/100 (C).
CDNA
Hold37
out of 100
Grade: F
DHR
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+57.7%
Fair Value
$46.59
Current Price
$28.82
$17.77 discount
Margin of Safety
-70.8%
Fair Value
$114.84
Current Price
$196.19
$81.35 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 39.0% year-over-year
Conservative balance sheet, low leverage
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Generating 1.1B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 1.5%
Weak financial health signals
Premium valuation, high expectations priced in
3.7% revenue growth
ROE of 7.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CDNA
The strongest argument for CDNA centers on Revenue Growth, Debt/Equity. Revenue growth of 39.0% demonstrates continued momentum.
Bull Case : DHR
The strongest argument for DHR centers on Market Cap, Price/Book, Operating Margin. PEG of 1.26 suggests the stock is reasonably priced for its growth.
Bear Case : CDNA
The primary concerns for CDNA are EPS Growth, Market Cap, Operating Margin.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Revenue Growth, Return on Equity.
Key Dynamics to Monitor
CDNA profiles as a hypergrowth stock while DHR is a value play — different risk/reward profiles.
CDNA carries more volatility with a beta of 2.48 — expect wider price swings.
CDNA is growing revenue faster at 39.0% — sustainability is the question.
DHR generates stronger free cash flow (1.1B), providing more financial flexibility.
Bottom Line
DHR scores higher overall (58/100 vs 37/100). CDNA offers better value entry with a 57.7% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CareDx Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?